title: Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family.
abstract: gp130 acts as a common transducing signal chain for all receptors belonging to the interleukin (IL)-6 receptor family. The IL-6-related cytokines [IL-6, IL-11, oncostatin M (OSM), leukemia inhibitory factor, ciliary neurotrophic factor, and cardiotrophin] often modulate tumor phenotype and control the proliferation of many tumor cell lines. We demonstrate that melanoma cell lines release, in vitro and in vivo (when transplanted in nude mice), soluble gp130 (sgp130), a potential antagonist of cytokines from the IL-6 family. Biochemical analysis revealed that sgp130 derived from melanoma patients' sera or from culture supernatants of melanoma cell lines is a Mr 104,000 protein that resolved after deglycosylation as a Mr 58,000 protein. PCR and Northern blot analysis only identified one gp130 membrane mRNA, suggesting that the soluble form of gp130 is generated by proteolytic cleavage. OSM reproducibly increases sgp130 released by melanoma cell lines, whereas leukemia inhibitory factor stimulates the production of sgp130 in only one of three cell lines tested. This tumor-derived sgp130 is functional because it binds in solution to the IL-6-soluble IL-6 receptor (gp80) complex. Recombinant sgp130 inhibits the growth inhibitory activity of the IL-6-soluble IL-6 receptor complex and OSM on some melanoma cell lines. Therefore, this soluble gp130 represents a natural antagonist of cytokines from the IL-6 family.
authors.affiliation: Immunotech S.A., 130 Avenue de Lattre de Tassigny, BP 177 F, 13276 Marseille Cedex 09, France.
authors.forename: F A
authors.initials: FA
authors.lastname: Montero-Julian
authors.forename: H
authors.initials: H
authors.lastname: Brailly
authors.forename: C
authors.initials: C
authors.lastname: Sautès
authors.forename: I
authors.initials: I
authors.lastname: Joyeux
authors.forename: T
authors.initials: T
authors.lastname: Dorval
authors.forename: V
authors.initials: V
authors.lastname: Mosseri
authors.forename: K
authors.initials: K
authors.lastname: Yasukawa
authors.forename: J
authors.initials: J
authors.lastname: Wijdenes
authors.forename: A
authors.initials: A
authors.lastname: Adler
authors.forename: I
authors.initials: I
authors.lastname: Gorin
authors.forename: W H
authors.initials: WH
authors.lastname: Fridman
authors.forename: E
authors.initials: E
authors.lastname: Tartour
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis / Q000502:physiology*; D020934:Ciliary Neurotrophic Factor; D050822:Cytokine Receptor gp130; D016207:Cytokines / Q000037:antagonists & inhibitors*; D005260:Female; D006131:Growth Inhibitors / Q000037:antagonists & inhibitors; D006801:Humans; D017370:Interleukin-11 / Q000037:antagonists & inhibitors; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000037:antagonists & inhibitors; D008545:Melanoma / Q000503:physiopathology*; D008562:Membrane Glycoproteins / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology*; D051379:Mice; D008819:Mice, Nude; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors; D053683:Oncostatin M; D010455:Peptides / Q000037:antagonists & inhibitors; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors / Q000502:physiology*; D015398:Signal Transduction; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured; D000093242:Interleukin-6 Inhibitors
chemical_list: D015703:Antigens, CD; D020934:Ciliary Neurotrophic Factor; D050822:Cytokine Receptor gp130; D016207:Cytokines; D006131:Growth Inhibitors; D017370:Interleukin-11; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; D008562:Membrane Glycoproteins; D009419:Nerve Tissue Proteins; D053683:Oncostatin M; D010455:Peptides; D019947:Receptors, Interleukin-6; D000093242:Interleukin-6 Inhibitors; C494199:IL6ST protein, human; C494200:Il6st protein, mouse; C507837:LIF protein, human; C507838:Lif protein, mouse; C508351:OSM protein, human; C508352:Osm protein, mouse